A Review of Malaria Vaccine Clinical Projects Based on the WHO Rainbow Table

Overview

Journal Malar J

Publisher Biomed Central

Specialty Tropical Medicine

Date 2012 Jan 11

PMID 22230255

Citations 111

Authors

Lauren Schwartz

Graham V Brown

Blaise Genton

Vasee S Moorthy

Affiliations

Soon will be listed here.

Abstract

Development and Phase 3 testing of the most advanced malaria vaccine, RTS,S/AS01, indicates that malaria vaccine R&D is moving into a new phase. Field trials of several research malaria vaccines have also confirmed that it is possible to impact the host-parasite relationship through vaccine-induced immune responses to multiple antigenic targets using different platforms. Other approaches have been appropriately tested but turned out to be disappointing after clinical evaluation. As the malaria community considers the potential role of a first-generation malaria vaccine in malaria control efforts, it is an apposite time to carefully document terminated and ongoing malaria vaccine research projects so that lessons learned can be applied to increase the chances of success for second-generation malaria vaccines over the next 10 years. The most comprehensive resource of malaria vaccine projects is a spreadsheet compiled by WHO thanks to the input from funding agencies, sponsors and investigators worldwide. This spreadsheet, available from WHO's website, is known as "the rainbow table". By summarizing the published and some unpublished information available for each project on the rainbow table, the most comprehensive review of malaria vaccine projects to be published in the last several years is provided below.

Citing Articles

Plasmodium Falciparum and mosquito vector IgG patterns across suspected malaria cases in Ghana.

Asare K, Kwapong S, Tey P, Sackey V, Nuvor S, Amoah L BMC Infect Dis. 2024; 24(1):1374.

PMID: 39623362 PMC: 11613542. DOI: 10.1186/s12879-024-10248-9.

A landscape review of malaria vaccine candidates in the pipeline.

Tajudeen Y, Oladipo H, Yusuff S, Abimbola S, Abdulkadir M, Oladunjoye I Trop Dis Travel Med Vaccines. 2024; 10(1):19.

PMID: 39085983 PMC: 11293096. DOI: 10.1186/s40794-024-00222-3.

Diversity and selection analyses identify transmission-blocking antigens as the optimal vaccine candidates in Plasmodium falciparum.

Ciubotariu I, Broyles B, Xie S, Thimmapuram J, Mwenda M, Mambwe B EBioMedicine. 2024; 106:105227.

PMID: 39018754 PMC: 11663769. DOI: 10.1016/j.ebiom.2024.105227.

Diversity and selection analyses identify transmission-blocking antigens as the optimal vaccine candidates in .

Ciubotariu I, Broyles B, Xie S, Thimmapuram J, Mwenda M, Mambwe B medRxiv. 2024; .

PMID: 38766239 PMC: 11100930. DOI: 10.1101/2024.05.11.24307175.

sensitivity of clinical isolates to 4-aminoquinolines in Northeast Nigeria.

Balogun S, Sandabe U, Waziri I, Jibrin J, Fehintola F Malariaworld J. 2024; 7:10.

PMID: 38601349 PMC: 11003210. DOI: 10.5281/zenodo.10818088.

References

Druilhe P, Spertini F, Soesoe D, Corradin G, Mejia P, Singh S . A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med. 2005; 2(11):e344. PMC: 1277929. DOI: 10.1371/journal.pmed.0020344. View

McConkey S, Reece W, Moorthy V, Webster D, Dunachie S, Butcher G . Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med. 2003; 9(6):729-35. DOI: 10.1038/nm881. View

Bojang K, Obaro S, DAlessandro U, Bennett S, Langerock P, Targett G . An efficacy trial of the malaria vaccine SPf66 in Gambian infants--second year of follow-up. Vaccine. 1998; 16(1):62-7. DOI: 10.1016/s0264-410x(97)00159-x. View

Lusingu J, Gesase S, Msham S, Francis F, Lemnge M, Seth M . Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months. Malar J. 2009; 8:163. PMC: 2720982. DOI: 10.1186/1475-2875-8-163. View

Wang R, Doolan D, Le T, Hedstrom R, Coonan K, Charoenvit Y . Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 1998; 282(5388):476-80. DOI: 10.1126/science.282.5388.476. View

Zavala F, Tam J, Hollingdale M, Cochrane A, Quakyi I, Nussenzweig R . Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science. 1985; 228(4706):1436-40. DOI: 10.1126/science.2409595. View

Thera M, Doumbo O, Coulibaly D, Laurens M, Kone A, Guindo A . Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial. PLoS One. 2010; 5(2):e9041. PMC: 2816207. DOI: 10.1371/journal.pone.0009041. View

Lopez J, Weilenman C, Audran R, Roggero M, Bonelo A, Tiercy J . A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans. Implications for vaccination strategies. Eur J Immunol. 2001; 31(7):1989-98. DOI: 10.1002/1521-4141(200107)31:7<1989::aid-immu1989>3.0.co;2-m. View

White N . A vaccine for malaria. N Engl J Med. 2011; 365(20):1926-7. DOI: 10.1056/NEJMe1111777. View

10.

Thera M, Doumbo O, Coulibaly D, Diallo D, Sagara I, Dicko A . Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial. PLoS Clin Trials. 2006; 1(7):e34. PMC: 1851722. DOI: 10.1371/journal.pctr.0010034. View

11.

Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert S, Nicosia A . Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun. 2009; 78(1):145-53. PMC: 2798185. DOI: 10.1128/IAI.00740-09. View

12.

Acosta C, Galindo C, Schellenberg D, Aponte J, Kahigwa E, Urassa H . Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania. Trop Med Int Health. 1999; 4(5):368-76. DOI: 10.1046/j.1365-3156.1999.00406.x. View

13.

Ellis R, Martin L, Shaffer D, Long C, Miura K, Fay M . Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults. PLoS One. 2010; 5(1):e8787. PMC: 2809736. DOI: 10.1371/journal.pone.0008787. View

14.

VanBuskirk K, ONeill M, De La Vega P, Maier A, Krzych U, Williams J . Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc Natl Acad Sci U S A. 2009; 106(31):13004-9. PMC: 2714279. DOI: 10.1073/pnas.0906387106. View

15.

Sardesai N, Weiner D . Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol. 2011; 23(3):421-9. PMC: 3109217. DOI: 10.1016/j.coi.2011.03.008. View

16.

Kubler-Kielb J, Majadly F, Biesova Z, Mocca C, Guo C, Nussenzweig R . A bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugates. Proc Natl Acad Sci U S A. 2010; 107(3):1172-7. PMC: 2824317. DOI: 10.1073/pnas.0913374107. View

17.

Gregson A, Oliveira G, Othoro C, Calvo-Calle J, Thorton G, Nardin E . Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein. PLoS One. 2008; 3(2):e1556. PMC: 2216688. DOI: 10.1371/journal.pone.0001556. View

18.

Prudhomme OMeara W, Mangeni J, Steketee R, Greenwood B . Changes in the burden of malaria in sub-Saharan Africa. Lancet Infect Dis. 2010; 10(8):545-55. DOI: 10.1016/S1473-3099(10)70096-7. View

19.

Moorthy V, Reed Z, Smith P . Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation. Vaccine. 2007; 25(28):5115-23. DOI: 10.1016/j.vaccine.2007.01.085. View

20.

Nebie I, Diarra A, Ouedraogo A, Tiono A, Konate A, Gansane A . Humoral and cell-mediated immunity to MSP3 peptides in adults immunized with MSP3 in malaria endemic area, Burkina Faso. Parasite Immunol. 2009; 31(8):474-80. PMC: 2759983. DOI: 10.1111/j.1365-3024.2009.01130.x. View